Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study creates an online cohort of sexual and gender minorities in Brazil to observe PrEP and ART use and adherence over one year through quarterly surveys. Participants on PrEP or ART are randomized to receive either a digital WhatsApp reminder program for six months or no digital intervention. The primary question is whether weekly WhatsApp messages can improve adherence to PrEP or ART. Data collection includes medication use, sexual behaviors, HIV testing, STIs, mental health, and experiences of discrimination in health services. The study is led by Oswaldo Cruz Foundation with site activities at Instituto Nacional de Infectologia Evandro Chagas in Rio de Janeiro.

Why it matters

Who can join: the full rules

Inclusion Criteria:

male sex assigned at birth and identifying as a man, travesti, transgender person, or non-binary person; age ≥18 years; residing in Brazil; access to the internet; and self-reporting sex with a man in the past 12 months.

Exclusion Criteria:

incorrectly answering the attention-check questions; and incomplete responses, defined as not reaching the end of the screening questionnaire

Where it's running

• Instituto Nacional de Infectologia Evandro Chagas
  Rio de Janeiro, Rio de Janeiro, Brazil Recruiting

Study contacts

• Study coordinator: Thiago S Torres, PhD
• Email: ttorres79@gmail.com
• Phone: +55 2138659128

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

• Mass Balance and Oral Bioavailability of a radiolabeled HIV drug

  This early-phase study tests how the radiolabeled VH4524184 is absorbed, distributed, metabolized, and excreted in adults with HIV.

  Recruiting Phase 1 ViiV Healthcare · Groningen · NCT07636928

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.